Navigation Links
GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
Date:12/5/2008

Presentations Will Highlight Research Conducted in GenVec Malaria Vaccine Program

GAITHERSBURG, Md., Dec. 5 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that the company will present on GenVec's malaria vaccine program at the American Society of Tropical Medicine and Hygiene (ASTMH) 57th Annual Meeting, which will take place in New Orleans, LA on December 7-11, 2008. Two presentations, highlighting research conducted in this program, will be given by GenVec scientists. Additional presentations, to be given by GenVec collaborators, will provide updates on malaria vaccine development, ranging from preclinical research through ongoing clinical studies using GenVec's core adenovector technology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO)

Joseph L. Bruder, Ph.D., GenVec's Director of Vector and Vaccine Programs, will give two research presentations: "Advanced generation adeno-based vectors for malaria vaccine development" and "Development of a multi-antigen multi-stage adenovector-based malaria vaccine that induces robust T-cell and antibody responses." These presentations will be available on GenVec's website on December 11, 2008. To view these presentations, visit www.genvec.com, click on "Investor Relations" and then "Webcasts and Data."

"Research presented at the ASTMH Annual meeting highlights the potential of GenVec's vaccine programs," stated Dr. Rick King, GenVec's Senior Vice President of Research. "We are excited about the prospective use of our technology in the prevention of malaria."

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. Additional clinical trials are in progress in rectal cancer, head and neck cancer, and melanoma. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and influenza. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.


'/>"/>
SOURCE GenVec, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
2. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
3. Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations
4. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
5. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
6. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
7. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
8. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
9. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
10. GeneThera Announces it is Set to Begin Commercial Testing for Johnes Disease as Soon as January, 2009.
11. Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B ... York City on October 11, 2017. , The annual award competition recognizes editorial and ...
Breaking Medicine News(10 mins):